Reteplase
 | This article relies largely or entirely on a single source. (September 2020) |
| Clinical data | |
|---|---|
| Trade names | Retavase, Retefuse, Rapilysin,Mirel, others |
| AHFS/Drugs.com | Monograph |
| License data | |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C1736H2671N499O522S22 |
| Molar mass | 39589.75 g·mol−1 |
| (verify) | |
Reteplase, trade names include Retavase, is a
clots
that cause them.
Reteplase is a recombinant non-glycosylated form of human
bacterium Escherichia coli.[citation needed
]
Reteplase was approved for use in 1996.[1]
Reteplase is similar to recombinant human tissue plasminogen activator (alteplase), but the modifications give reteplase a longer half-life of 13–16 minutes. Reteplase also binds fibrin with lower affinity than alteplase, improving its ability to penetrate into clots.
As reteplase is able to penetrate inside the thrombi, an enhanced fibrinolytic activity will be achieved → rapid reperfusion → low incidence of bleeding.
References
- PMID 31016177.